Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 91 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2015', provides an overview of the Chemotherapy Induced Nausea and Vomiting's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Nausea and Vomiting, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Nausea and Vomiting and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chemotherapy Induced Nausea and Vomiting and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chemotherapy Induced Nausea and Vomiting products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chemotherapy Induced Nausea and Vomiting pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chemotherapy Induced Nausea and Vomiting Overview 8
Therapeutics Development 9
Pipeline Products for Chemotherapy Induced Nausea and Vomiting - Overview 9
Pipeline Products for Chemotherapy Induced Nausea and Vomiting - Comparative Analysis 10
Chemotherapy Induced Nausea and Vomiting - Therapeutics under Development by Companies 11
Chemotherapy Induced Nausea and Vomiting - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Chemotherapy Induced Nausea and Vomiting - Products under Development by Companies 17
Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development 19
Acacia Pharma Ltd. 19
Aphios Corporation 20
Genovate Biotechnology Co., LTD. 21
Helsinn Holding S.A. 22
Heron Therapeutics, Inc. 23
INSYS Therapeutics, Inc. 24
Kyowa Hakko Kirin Co., Ltd. 25
Merck & Co., Inc. 26
RedHill Biopharma Ltd. 27
Shin Nippon Biomedical Laboratories, Ltd. 28
Sparsha Pharma International Pvt. Ltd. 29
Suda Ltd 30
Teikoku Pharma USA, Inc. 31
Tesaro, Inc. 32
Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Target 35
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 42
(netupitant + palonosetron hydrochloride) - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
APD-403 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
APD-421 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
aprepitant - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
aprepitant - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
dronabinol - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
dronabinol - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Drug to Antagonize 5-HT3 for Chemotherapy Induced Nausea and Vomiting - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
granisetron - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
granisetron - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
granisetron ER - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
granisetron ER - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ondansetron hydrochloride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ondansetron hydrochloride - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ondansetron hydrochloride CR - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
rolapitant hydrochloride - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
TPW-146 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Chemotherapy Induced Nausea and Vomiting - Recent Pipeline Updates 66
Chemotherapy Induced Nausea and Vomiting - Dormant Projects 80
Chemotherapy Induced Nausea and Vomiting - Discontinued Products 81
Chemotherapy Induced Nausea and Vomiting - Product Development Milestones 82
Featured News & Press Releases 82
Jan 12, 2015: Insys Therapeutics Plans to Submit NDA for Dronabinol Oral Solution in First Quarter of 2015 82
Jan 12, 2015: Insys Therapeutics To Initiate Phase III Pivotal PK Study For Ondansetron 82
Dec 31, 2014: RedHill Biopharma Announces Acceptance for Review of BEKINDA European Marketing Application for Oncology Support 82
Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support 83
Nov 06, 2014: Heron Therapeutics Discloses HTX-019 Intravenous Formulation of NK-1 Receptor Antagonist for Prevention of CINV 85
Nov 06, 2014: Heron Therapeutics Discloses New Proprietary Intravenous Formulation of NK-1 Receptor Antagonist for Prevention of CINV 85
Oct 10, 2014: FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy 86
Sep 27, 2014: Rolapitant Reduces Nausea and Vomiting in Phase III Trial 86
Sep 08, 2014: OPKO Licensee TESARO Submits New Drug Application for Rolapitant 87
Jul 10, 2014: Helsinn Announces That Phase 2/3 Pivotal Trials for NEPA (netupitant 300mg + oral palonosetron 0.50mg), Will be Published in the Annals of Oncology 88
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 91
Disclaimer 91

List of Tables
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2015 9
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Comparative Analysis by Unknown Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Ltd., H1 2015 19
Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corporation, H1 2015 20
Chemotherapy Induced Nausea and Vomiting - Pipeline by Genovate Biotechnology Co., LTD., H1 2015 21
Chemotherapy Induced Nausea and Vomiting - Pipeline by Helsinn Holding S.A., H1 2015 22
Chemotherapy Induced Nausea and Vomiting - Pipeline by Heron Therapeutics, Inc., H1 2015 23
Chemotherapy Induced Nausea and Vomiting - Pipeline by INSYS Therapeutics, Inc., H1 2015 24
Chemotherapy Induced Nausea and Vomiting - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 25
Chemotherapy Induced Nausea and Vomiting - Pipeline by Merck & Co., Inc., H1 2015 26
Chemotherapy Induced Nausea and Vomiting - Pipeline by RedHill Biopharma Ltd., H1 2015 27
Chemotherapy Induced Nausea and Vomiting - Pipeline by Shin Nippon Biomedical Laboratories, Ltd., H1 2015 28
Chemotherapy Induced Nausea and Vomiting - Pipeline by Sparsha Pharma International Pvt. Ltd., H1 2015 29
Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Ltd, H1 2015 30
Chemotherapy Induced Nausea and Vomiting - Pipeline by Teikoku Pharma USA, Inc., H1 2015 31
Chemotherapy Induced Nausea and Vomiting - Pipeline by Tesaro, Inc., H1 2015 32
Assessment by Monotherapy Products, H1 2015 33
Assessment by Combination Products, H1 2015 34
Number of Products by Stage and Target, H1 2015 36
Number of Products by Stage and Mechanism of Action, H1 2015 38
Number of Products by Stage and Route of Administration, H1 2015 40
Number of Products by Stage and Molecule Type, H1 2015 41
Chemotherapy Induced Nausea and Vomiting Therapeutics - Recent Pipeline Updates, H1 2015 66
Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H1 2015 80
Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H1 2015 81